Physician profile
Richard Cooper
NPI 1942207634
$10,752.32
in general payments reported to CMS, 2019-2025
34 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $1,556 · 2021: $1,859 · 2022: $1,343 · 2023: $1,551 · 2024: $1,527 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,305.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,292.97 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,049.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $867.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $772.68 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $651.74 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $479.59 | 2019-2021 | |
| Astellas Pharma US INC | $463.26 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $448.87 | 2019-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $415.83 | 2021-2025 | |
| Amgen INC. | $312.48 | 2019-2025 | Evenity, Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $303.47 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $300.25 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $299.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $297.04 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $216.93 | 2020-2025 | Nexletol |
| Exact Sciences Corporation | $213.47 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $189.64 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $158.95 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $145.34 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.86 | 2019-2024 | Xifaxan |
| Bridgebio Pharma, INC. | $91.72 | 2025 | Attruby |
| Medtronic Vascular, INC. | $77.87 | 2019 | |
| Sunovion Pharmaceuticals INC. | $68.34 | 2021-2022 | |
| Genentech USA, INC. | $47.52 | 2020-2021 | |
| Horizon Therapeutics Plc | $28.40 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $27.81 | 2023 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $22.68 | 2019 | |
| Seqirus USA INC | $20.23 | 2025 | Fluad, Flucelvax |
| Abiomed | $19.15 | 2024 | Impella |
| Boston Scientific Corporation | $19.08 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.09 | 2023 | |
| Bausch Health US, LLC | $10.83 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.80 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.